Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021

Vista sencilla de ítem
dc.contributor.advisorCano Rivera, Rodolfo
dc.contributor.advisorVarela Prieto, Lourdes
dc.contributor.authorMurgas Cañas, Carlos Hernando
dc.contributor.authorOspino Guerra, María Clara
dc.coverage.spatialBarranquillaspa
dc.creator.emailcarlosh-murgasc@unilibre.edu.cospa
dc.creator.emailmariac-ospinog@unilibre.edu.cospa
dc.date.accessioned2024-02-07T19:42:41Z
dc.date.available2024-02-07T19:42:41Z
dc.date.created2023
dc.description.abstractObjetivo: Determinar el valor predictivo de las troponinas cardíacas para mortalidad intrahospitalaria en adultos hospitalizados con COVID-19 durante enero a junio de 2021. Materiales y métodos: Estudio de casos y controles anidado en una cohorte retrospectiva, que incluyó sujetos de 18 años en adelante con diagnóstico confirmado de COVID-19 hospitalizados entre enero y junio de 2021; se describieron las variables demográficas y paraclínicas de los pacientes y su relación con la condición al egreso; se estimaron las características operativas (sensibilidad, especificidad y valores predictivos) de las troponinas elevadas frente a la mortalidad. Resultados: Se incluyeron 358 participantes, de los cuales 47,8% eran mujeres, la edad promedio fue de 65,1+/-14,9 años. Las comorbilidades más frecuentes fueron hipertensión arterial (53,1%), obesidad (31,6%) y diabetes mellitus (21,5%). Todas las variables estudiadas (excepto el sexo) presentaron diferencias estadísticamente significativas (p<0,05) respecto a mortalidad, siendo la elevación de troponinas el principal factor, con un OR de 9,4 (IC95%: 5,5-16,0). Los pacientes con elevación de troponinas presentaron una mortalidad intrahospitalaria mayor (55,6%) frente al grupo sin elevación (11,7%). La sensibilidad y especificidad de este biomarcador fue de 77,9% y 72,7% respectivamente. El valor predictivo positivo de la elevación de troponinas fue de 55,6% y su valor predictivo negativo fue de 88,3% para mortalidad intrahospitalaria. Conclusión: La elevación de troponinas en los sujetos con COVID-19 tiene una correlación positiva con la mortalidad intrahospitalaria de forma independiente a otras condiciones como grupo etario, comorbilidades o requerimiento de oxigenoterapia. Por otro lado, las troponinas normales tienen un buen valor predictivo negativo que permite predecir mayor probabilidad de supervivencia al egreso.spa
dc.description.abstractenglishObjective: To determine the predictive value of cardiac troponins for in-hospital mortality in hospitalized adults with COVID-19 from January to June 2021. Methods and materials: Cases and controls nested in a retrospective cohort study. It included people with 18 years old and older with a confirmed diagnosis of COVID-19 hospitalized between January and June 2021, the demographic and paraclinical variables of them and their relationship with the final condition of the patient were described. There were estimated sensibility, specificity, and predictive values of high troponins with respect of mortality. Results: There were included 358 patients, of whom 47.8% were women, and the average age was 65.1+/-14.9 years. The most frequent comorbidities were hypertension (53.1%), obesity (31.6%) and diabetes mellitus (21.5%). All the variables studied (except sex) had statistically significant differences (p<0.05) with mortality, with troponin elevation being the main factor, with an OR of 9.4 (95% CI: 5.5-16.0). Patients with troponin elevation had higher in-hospital mortality (55.6%) compared with the non-elevation group (11.7%). The sensitivity and specificity of this biomarker was 77.9% and 72.7% respectively. The positive predictive value of troponin elevation was 55.6% and its negative predictive value was 88.3% for in-hospital mortality. Conclusion: Troponin elevation in patients with COVID-19 has a positive correlation with in-hospital mortality independently of other conditions such as age, comorbidities, or oxygen therapy requirement. On the other hand, normal troponins have a good negative predictive value that allows predicting a greater probability of survival at discharge.spa
dc.description.sponsorshipUniversidad Libre Seccional Barranquilla -- Facultad de Ciencias de la Salud -- Especialización en Medicina Internaspa
dc.description.sponsorshipGhio S, Montalto C, Pagnesi M, Lupi L, Cappelletti A, Baldetti L, et al. High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? J Cardiovasc Med (Hagerstown). 2021;22(11):828– 31spa
dc.formatPDFspa
dc.identifier.urihttps://hdl.handle.net/10901/28377
dc.relation.referencesWoodall MNJ, Masonou T, Case KM, Smith CM. Human models for COVID- 19 research. J Physiol. 2021;599(18):4255–67spa
dc.relation.referencesGautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020;16(12):1159–84spa
dc.relation.referencesZheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25spa
dc.relation.referencesTian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta- analysis. J Med Virol. 2020;92(10):1875–83spa
dc.relation.referencesZinellu A, Sotgia S, Fois AG, Mangoni AA. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta- regression. Adv Med Sci. 2020;66(2):304–14spa
dc.relation.referencesBeltrán FM. La Sociedad Colombiana de Cardiología y Cirugía Cardiovascular y la pandemia COVID-19. Rev Colomb Cardiol. 2020;27(2):69–72spa
dc.relation.referencesSaavedra CA. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio. 2020;24(3):1–2spa
dc.relation.referencesGao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):1–7spa
dc.relation.referencesMcKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol. 2021;37(8):1165–74spa
dc.relation.referencesCañón-Montañez W, Santos ÁBS, Foppa M. Strain longitudinal global: un parámetro útil para evaluar disfunción ventricular izquierda subclínica en el síndrome metabólico. Rev Colomb Cardiol. 2016;23(2):112–9spa
dc.relation.referencesSun W, Zhang Y, Wu C, Xie Y, Peng L, Nie X, et al. Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients. Echocardiography. 2021;38(8):1272–81spa
dc.relation.referencesParis S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, et al. 60 Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study. Europace. 2021;23(10):1603–11spa
dc.relation.referencesHendren NS, Drazner MH, Bozkurt B. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome Middle Eastern respiratory syndrome. Circulation. 2020;9(141):1903–1914spa
dc.relation.referencesSattar Y, Ullah W, Rauf H, Virk H ul H, Yadav S, Chowdhury M, et al. COVID- 19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Hear Vasc [Internet]. 2020;29(2020):100589. Available from: https://doi.org/10.1016/j.ijcha.2020.100589spa
dc.relation.referencesCannata F, Bombace S, Stefanini GG. Marcadores cardiacos en pacientes con COVID-19: un instrumento práctico en tiempos difíciles. Rev Española Cardiol. 2021;10–2spa
dc.relation.referencesStefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8spa
dc.relation.referencesQin JJ, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension. 2020;1104–12spa
dc.relation.referencesZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62spa
dc.relation.referencesDeng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. Clin Chim Acta [Internet]. 2020; 510:186–90. Available from: https://doi.org/10.1016/j.cca.2020.07.018spa
dc.relation.referencesJunior GLG de A, Braga F, Jorge JK, Nobre GF, Kalichsztein M, de Faria P de MP, et al. Prognostic value of troponin-t and b-type natriuretic peptide in patients hospitalized for covid-19. Arq Bras Cardiol. 2020;115(4):660–6spa
dc.relation.referencesOmland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(19):1878–80spa
dc.relation.referencesMetkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute 61 Respiratory Distress Syndrome. Circulation. 2021;553–65spa
dc.relation.referencesGuo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8spa
dc.relation.referencesYu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4spa
dc.relation.referencesMadjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831–40spa
dc.relation.referencesClerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A, et al. COVID- 19 and cardiovascular disease. Circulation. 2020;141(20):1648–55spa
dc.relation.referencesHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506spa
dc.relation.referencesYang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol. 2020;30(5):2616–26spa
dc.relation.referencesVélez M, Velásquez P, Acosta J, Vera C, Santiago J, Jimenez C, et al. Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NSspa
dc.relation.referencesManocha KK, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the Ha2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021;10(6spa
dc.relation.referencesShi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10spa
dc.relation.referencesSmilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun;42(23):2270–9spa
dc.relation.referencesYitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 62 disease: A systematic review. SAGE open Med. 2021; 9:20503121211050756spa
dc.relation.referencesSoni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245–9spa
dc.relation.referencesYao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020; 8:49spa
dc.relation.referencesBartziokas K, Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Vol. 156, Medicina clinica. Spain; 2021. p. 37spa
dc.relation.referencesDeng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021 Apr;156(7):324–31spa
dc.relation.referencesMesas AE, Cavero-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11 November):1–23spa
dc.relation.referencesMoutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One [Internet]. 2020;15(10 October):1–25. Available from: http://dx.doi.org/10.1371/journal.pone.0239802spa
dc.relation.referencesGhahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res [Internet]. 2020;25(1):1–10. Available from: https://doi.org/10.1186/s40001-020-00432-3spa
dc.relation.referencesAli AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, Inflamm Dis. 2022;10(3):1–10spa
dc.relation.referencesVelavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95(January):304–7spa
dc.relation.referencesMcKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol [Internet]. 2020; Available from: https://doi.org/10.1016/j.cjca.2020.11.007spa
dc.relation.referencesPapageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol [Internet]. 2022;77(1):81–8. Available from: https://doi.org/10.1080/00015385.2021.1887586spa
dc.relation.referencesZhu F, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(January):164–71spa
dc.relation.referencesAl B, Torres P, Ramos-tuarez F, Dewaswala N, Abdallah A. Cardiac Troponin- I and COVID-19: A Prognostic Tool for In-Hospital Mortality. 2020;11(6):398– 404spa
dc.relation.referencesWang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9spa
dc.relation.referencesPonti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from: https://doi.org/10.1080/10408363.2020.1770685spa
dc.relation.referencesImazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020 Aug;106(15):1127–31spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.subjectCOVID-19spa
dc.subjectMortalidadspa
dc.subjectTroponinasspa
dc.subjectValor predictivospa
dc.subjectInjuria miocárdicaspa
dc.subject.lembTroponinaspa
dc.subject.lembInfecciones por coronavirus - mortalidadspa
dc.subject.lembInfarto del miocardiospa
dc.subject.subjectenglishCOVID-19spa
dc.subject.subjectenglishMortalityspa
dc.subject.subjectenglishTroponinsspa
dc.subject.subjectenglishPredictive valuespa
dc.subject.subjectenglishMyocardial injuryspa
dc.titleValor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021spa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 2 de 2
Miniatura
Nombre:
MURGAS.pdf
Tamaño:
1.18 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Miniatura
Nombre:
FORMULARIO AUTORIZACION.pdf
Tamaño:
622.28 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna